GENESIS THERAPEUTICS
Live / Applied — Second extension granted (statement of use) (as of 13 Aug 2025)
What this means for you
Not registered yet, but its 09 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97259016
- Mark type
- Stylized text
- Filed
- 09 Feb 2022
- Published for opposition
- 02 Jul 2024
- Attorney of record
- EMILIA F. CANNELLA
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the treatment of rare autoimmune and immune-system-related diseases and disorders; all of the foregoing excluding preparations for the treatment of ocular and opthalmic diseases and disorders
Owner
- GENESIS MOLECULAR AI, INC., BURLINGAME, CA, US
- Genesis Therapeutics, Inc., Burlingame, CA, US
- Genesis Therapeutics, Inc., Burlingame, CA, US
Prosecution history
- 11 Feb 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 05 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 14 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2025 — SOU EXTENSION 2 GRANTED
- 13 Aug 2025 — SOU EXTENSION 2 FILED
- 13 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Feb 2025 — SOU EXTENSION 1 GRANTED
- 06 Feb 2025 — SOU EXTENSION 1 FILED
- 06 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 27 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Jul 2024 — PUBLISHED FOR OPPOSITION
- 12 Jun 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 28 May 2024 — EXPARTE APPEAL TERMINATED